|
1
|
El-Serag HB: Epidemiology of viral
hepatitis and hepatocellular carcinoma. Gastroenterology.
142:1264–1273.e1. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
El-Serag HB: Hepatocellular carcinoma. N
Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
McGlynn KA, Petrick JL and London WT:
Global epidemiology of hepatocellular carcinoma: An emphasis on
demographic and regional variability. Clin Liver Dis. 19:223–238.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Singal AG and El-Serag HB: Hepatocellular
carcinoma from epidemiology to prevention: Translating knowledge
into practice. Clin Gastroenterol Hepatol. 13:2140–2151. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Osaki Y and Nishikawa H: Treatment for
hepatocellular carcinoma in Japan over the last three decades: Our
experience and literature review. Hepatol Res. 45:59–74. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rahbari NN, Mehrabi A, Mollberg NM, Müller
SA, Koch M, Büchler MW and Weitz J: Hepatocellular carcinoma:
Current management and perspectives for the future. Ann Surg.
253:453–469. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: A phase III randomised, double-blind,
placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Di Marco V, De Vita F, Koskinas J, Semela
D, Toniutto P and Verslype C: Sorafenib: From literature to
clinical practice. Ann Oncol. 24 Suppl 2:ii30–ii37. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sangiovanni A and Colombo M: Treatment of
hepatocellular carcinoma: Beyond international guidelines. Liver
Int. 36 Suppl 1:S124–S129. 2016. View Article : Google Scholar
|
|
11
|
Arizumi T, Ueshima K, Minami T, Kono M,
Chishina H, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, et al:
Effectiveness of sorafenib in patients with transcatheter arterial
chemoembolization (TACE) refractory and intermediate-stage
hepatocellular carcinoma. Liver Cancer. 4:253–226. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bruix J, Raoul JL, Sherman M, Mazzaferro
V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M,
Sangiovanni A, et al: Efficacy and safety of sorafenib in patients
with advanced hepatocellular carcinoma: Subanalyses of a phase III
trial. J Hepatol. 57:821–829. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Llovet JM, Peña CE, Lathia CD, Shan M,
Meinhardt G and Bruix J: SHARP Investigators Study Group. Plasma
biomarkers as predictors of outcome in patients with advanced
hepatocellular carcinoma. Clin Cancer Res. 18:2290–2300. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ogasawara S, Chiba T, Ooka Y, Suzuki E,
Kanogawa N, Saito T, Motoyama T, Tawada A, Kanai F and Yokosuka O:
Liver function assessment according to the Albumin-Bilirubin (ALBI)
grade in sorafenib-treated patients with advanced hepatocellular
carcinoma. Invest New Drugs. 33:1257–1262. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Choi GH, Shim JH, Kim MJ, Ryu MH, Ryoo BY,
Kang YK, Shin YM, Kim KM, Lim YS and Lee HC: Sorafenib alone versus
sorafenib combined with transarterial chemoembolization for
advanced-stage hepatocellular carcinoma: Results of propensity
score analyses. Radiology. 269:603–611. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kudo M, Matsui O, Izumi N, Kadoya M,
Okusaka T, Miyayama S, Yamakado K, Tsuchiya K, Ueshima K, Hiraoka
A, et al: Transarterial chemoembolization failure/refractoriness:
JSH-LCSGJ criteria 2014 update. Oncology. 87 Suppl 1:S22–S31. 2014.
View Article : Google Scholar
|
|
17
|
Printz C: Clinical trials of note.
Sorafenib as adjuvant treatment in the prevention of disease
recurrence in patients with hepatocellular carcinoma (HCC) (STORM).
Cancer. 115:46462009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Prado CM, Lieffers JR, McCargar LJ, Reiman
T, Sawyer MB, Martin L and Baracos VE: Prevalence and clinical
implications of sarcopenic obesity in patients with solid tumors of
the respiratory and gastrointestinal tracts: A population based
study. Lancet Oncol. 9:629–635. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rosenberg IH: Sarcopenia: Origins and
clinical relevance. J Nutr. 127:990S–991S. 1997.PubMed/NCBI
|
|
20
|
Wang C and Bai L: Sarcopenia in the
elderly: Basic and clinical issues. Geriatr Gerontol Int.
12:388–396. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dasarathy S: Consilience in sarcopenia of
cirrhosis. J Cachexia Sarcopenia Muscle. 3:225–237. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Periyalwar P and Dasarathy S: Malnutrition
in cirrhosis: Contribution and consequences of sarcopenia on
metabolic and clinical responses. Clin Liver Dis. 16:95–131. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nishikawa H, Yoh K, Enomoto H, Iwata Y,
Kishino K, Shimono Y, Hasegawa K, Nakano C, Takata R, Nishimura T,
et al: Factors associated with protein-energy malnutrition in
chronic liver disease: Analysis using indirect calorimetry.
Medicine (Baltimore). 95:e24422016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fukushima H, Nakanishi Y, Kataoka M,
Tobisu K and Koga F: Prognostic significance of sarcopenia in
patients with metastatic renal cell carcinoma. J Urol. 195:26–32.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Levolger S, van Vugt JL, de Bruin RW and
Ijzermans JN: Systematic review of sarcopenia in patients operated
on for gastrointestinal and hepatopancreatobiliary malignancies. Br
J Surg. 102:1448–1458. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kobayashi A, Kaido T, Hamaguchi Y, Okumura
S, Taura K, Hatano E, Okajima H and Uemoto S: Impact of
postoperative changes in sarcopenic factors on outcomes after
hepatectomy for hepatocellular carcinoma. J Hepatobiliary Pancreat
Sci. 23:57–64. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Harimoto N, Shirabe K, Yamashita YI,
Ikegami T, Yoshizumi T, Soejima Y, Ikeda T, Maehara Y, Nishie A and
Yamanaka T: Sarcopenia as a predictor of prognosis in patients
following hepatectomy for hepatocellular carcinoma. Br J Surg.
100:1523–1530. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Takeda H, Nishikawa H, Osaki Y, Tsuchiya
K, Joko K, Ogawa C, Taniguchi H, Orito E, Uchida Y and Izumi N;
Japanese Red Cross Liver Study Group, : Clinical features
associated with radiological response to sorafenib in unresectable
hepatocellular carcinoma: A large multicenter study in Japan. Liver
Int. 35:1581–1589. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nishikawa H, Takeda H, Tsuchiya K, Joko K,
Ogawa C, Taniguchi H, Orito E, Uchida Y, Osaki Y and Izumi N;
Japanese Red Cross Liver Study Group, : Sorafenib therapy for BCLC
stage B/C hepatocellular carcinoma; clinical outcome and safety in
aged patients: A multicenter study in Japan. J. Cancer. 5:499–509.
2014. View Article : Google Scholar
|
|
30
|
Cheng AL, Amarapurkar D, Chao Y, Chen PJ,
Geschwind JF, Goh KL, Han KH, Kudo M, Lee HC, Lee RC, et al:
Re-evaluating transarterial chemoembolization for the treatment of
hepatocellular carcinoma: Consensus recommendations and review by
an International Expert Panel. Liver Int. 34:174–183. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fujiwara N, Nakagawa H, Kudo Y, Tateishi
R, Taguri M, Watadani T, Nakagomi R, Kondo M, Nakatsuka T, Minami
T, et al: Sarcopenia, intramuscular fat deposition, and visceral
adiposity independently predict the outcomes of hepatocellular
carcinoma. J Hepatol. 63:131–140. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Trotti A, Colevas AD, Setser A, Rusch V,
Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN and
Rubin P: CTCAE v3.0: Development of a comprehensive grading system
for the adverse effects of cancer treatment. Semin Radiat Oncol.
13:176–181. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
European Association For The Study Of The
Liver; European Organisation For Research And Treatment Of Cancer,
. EASL-EORTC Clinical Practice guidelines: Management of
hepatocellular carcinoma. J Hepatol. 56:908–943. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lencioni R and Llovet JM: Modified RECIST
(mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis.
30:52–60. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Salvaggio G, Furlan A, Agnello F, Cabibbo
G, Marin D, Giannitrapani L, Genco C, Midiri M, Lagalla R and
Brancatelli G: Hepatocellular carcinoma enhancement on
contrast-enhanced CT and MR imaging: Response assessment after
treatment with sorafenib: Preliminary results. Radiol Med.
119:215–221. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Albers I, Hartmann H, Bircher J and
Creutzfeldt W: Superiority of the Child-Pugh classification to
quantitative liver function tests for assessing prognosis of liver
cirrhosis. Scand J Gastroenterol. 24:269–276. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Saito M, Seo Y, Yano Y, Miki A, Yoshida M
and Azuma T: Short-term reductions in non-protein respiratory
quotient and prealbumin can be associated with the long-term
deterioration of liver function after transcatheter arterial
chemoembolization in patients with hepatocellular carcinoma. J
Gastroenterol. 47:704–714. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hanai T, Shiraki M, Ohnishi S, Miyazaki T,
Ideta T, Kochi T, Imai K, Suetsugu A, Takai K, Moriwaki H and
Shimizu M: Rapid skeletal muscle wasting predicts worse survival in
patients with liver cirrhosis. Hepatol Res. 46:743–751. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chindapasirt J: Sarcopenia in Cancer
Patients. Asian Pac J Cancer Prev. 16:8075–8077. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mir O, Coriat R, Blanchet B, Durand JP,
Boudou-Rouquette P, Michels J, Ropert S, Vidal M, Pol S, Chaussade
S and Goldwasser F: Sarcopenia predicts early dose-limiting
toxicities and pharmacokinetics of sorafenib in patients with
hepatocellular carcinoma. PLoS One. 7:e375632012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shiraki M, Nishiguchi S, Saito M, Fukuzawa
Y, Mizuta T, Kaibori M, Hanai T, Nishimura K, Shimizu M, Tsurumi H
and Moriwaki H: Nutritional status and quality of life in current
patients with liver cirrhosis as assessed in 2007–2011. Hepatol
Res. 43:106–112. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Prado CM, Wells JC, Smith SR, Stephan BC
and Siervo M: Sarcopenic obesity: A Critical appraisal of the
current evidence. Clin Nutr. 31:583–601. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
McCurry J: Japan battles with obesity.
Lancet. 369:451–452. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Examination Committee of Criteria for
‘Obesity Disease’ in Japan; Japan Society for the Study of Obesity,
. New criteria for ‘obesity disease’ in Japan. Circ J. 66:987–992.
2002. View Article : Google Scholar : PubMed/NCBI
|
